pulmonary alveolar proteins pap sever autoimmune disease caps autoantibodi neutral mcs result impair function macrophages studi character patient find format mutant critic determine specify selfantigen individual antibody partial active use vitro bioassay depend experiment conduit inject mouse together human lead accueil lang pool circus remain bioavail contrast combine three noncrosscompet complete neutral request cytokine highmolecularweight complex vivo promote rapid degrade gmcsfcontain immune depend manner taken find provide plausible explain phenotype safety treatment base single antigmcsf monoclonal 